Veracyte, Inc.
VCYT
$46.16
-$0.23-0.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.41% | 19.91% | 23.42% | 23.46% | 23.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.41% | 19.91% | 23.42% | 23.46% | 23.95% |
| Cost of Revenue | 12.99% | 15.61% | 15.96% | 20.52% | 16.33% |
| Gross Profit | 17.89% | 21.80% | 26.84% | 24.80% | 27.56% |
| SG&A Expenses | 5.97% | 8.10% | 8.72% | 8.40% | 11.45% |
| Depreciation & Amortization | -15.00% | -19.85% | -23.77% | -27.81% | -25.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.50% | 9.49% | 10.70% | 11.94% | 14.35% |
| Operating Income | 409.29% | 3,972.03% | 372.39% | 221.68% | 153.29% |
| Income Before Tax | 479.51% | 152.87% | 149.81% | 133.60% | 83.52% |
| Income Tax Expenses | -36.83% | 451.20% | 190.19% | 172.74% | 193.32% |
| Earnings from Continuing Operations | 427.11% | 148.73% | 148.48% | 132.44% | 81.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 427.11% | 148.73% | 148.48% | 132.44% | 81.45% |
| EBIT | 409.29% | 3,972.03% | 372.39% | 221.68% | 153.29% |
| EBITDA | 122.56% | 152.63% | 319.05% | 381.49% | 338.37% |
| EPS Basic | 375.89% | 145.78% | 145.78% | 130.60% | 79.63% |
| Normalized Basic EPS | 151.16% | 311.22% | 1,548.62% | 437.55% | 279.30% |
| EPS Diluted | 349.37% | 143.73% | 143.67% | 128.80% | 78.16% |
| Normalized Diluted EPS | 151.74% | 307.01% | 1,519.76% | 431.16% | 276.66% |
| Average Basic Shares Outstanding | 3.76% | 4.65% | 5.47% | 5.28% | 4.19% |
| Average Diluted Shares Outstanding | 4.79% | 6.37% | 7.65% | 6.79% | 4.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |